Fungemia in COVID-19 ICU patients, a single medical center experience #MMPMID33107617
Bishburg E; Okoh A; Nagarakanti SR; Lindner M; Migliore C; Patel P
J Med Virol 2021[May]; 93 (5): 2810-2814 PMID33107617show ga
A known proportion of patients who are admitted for the novel coronavirus disease 2019 (COVID-19) requires intensive care unit (ICU) level of care. Prolonged ICU stay is a risk factor for the development of nosocomial candidemia. The current study aimed to investigate the incidence and risk factors associated with the development of nosocomial candidemia among patients admitted to the ICU for COVID-19. Patients who developed nosocomial candidemia were identified, and their clinical course was reported. A 1:3 case control matching was used to identify non-candidemia patients who served as controls. 89 patients were admitted to the ICU for COVID-19 during the study period. The incidence of nosocomial candidemia was 8.9% (n = 8). Case-control matching identified 24 patients with similar disease severity at the time of ICU admission. Median time to first isolation of yeast was 26 days. Candidemia patients reported longer median ICU stay than controls. (40 vs. 10 days, p = .004). In hospital death rates were comparable in both groups (38% vs. 54%, p = .548). Prolonged mechanical ventilation support was associated with the development of nosocomial candidemia.
|Adult[MESH]
|Aged[MESH]
|COVID-19/*epidemiology[MESH]
|Case-Control Studies[MESH]
|Cross Infection/*epidemiology[MESH]
|Female[MESH]
|Fungemia/*epidemiology[MESH]
|Hospital Mortality[MESH]
|Hospitals, Teaching[MESH]
|Humans[MESH]
|Incidence[MESH]
|Intensive Care Units/*statistics & numerical data[MESH]
J+Med+Virol 2021 ; 93 (5): 2810-2814
